Last €27.37 EUR
Change Today -0.049 / -0.18%
Volume 15.0
RHO6 On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 9:35 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHO6) Snapshot

Open
€27.53
Previous Close
€27.42
Day High
€27.63
Day Low
€27.37
52 Week High
02/27/14 - €28.75
52 Week Low
08/1/13 - €22.91
Market Cap
188.1B
Average Volume 10 Days
76.4
EPS TTM
--
Shares Outstanding
5.6B
EX-Date
03/6/14
P/E TM
--
Dividend
€1.08
Dividend Yield
2.92%
Current Stock Chart for ROCHE HOLDINGS LTD-SPONS ADR (RHO6)

roche holdings ltd-spons adr (RHO6) Related Bloomberg News

View More Bloomberg News

roche holdings ltd-spons adr (RHO6) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holdings ltd-spons adr (RHO6) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holdings ltd-spons adr (RHO6) Key Developments

Advanced Biological Laboratories and Roche Diagnostics International Renew and Extend Their Collaboration Agreement to Promote Their Next-Generation Sequencing, Genotyping and Drug Resistance Products

Advanced Biological Laboratories announced the renewal of a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories. This collaboration agreement is intended to develop a strategy to promote ABL products especially its next-generation sequencing platform DeepChek(R) together with Roche's next generation sequencing systems (GS Junior and GS FLX+ Sequencing Systems) for molecular virology. The principal objectives of the collaboration are to provide its mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity and meaningful genotyping and drug resistance reporting for personal healthcare. The collaboration has been extended from HIV to viral hepatitis B and C.

Roche Holding AG Reports Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Year 2014

Roche Holding AG reported earnings results for the first half of 2014. For the period, the company's net profit drop 7% compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units. Sales were CHF 22.974 billion, down 1% from CHF 23.295 billion from a year ago. Core operating profit was CHF 9,410 million against CHF 9,488 million a year ago. Operating free cash flow was CHF 7,869 million against CHF 7,445 million a year ago. Net income was CHF 5,641 million against CHF 6,047 million a year ago. Diluted core earnings per share were CHF 7.57 against CHF 7.58 a year ago. For the full year 2014, the company expects low- to mid-single digit growth in Group sales at constant exchange rates. Core EPS is targeted to grow ahead of sales.

Roche Holding Seeks Acquisitions

Roche Holding AG (SWX:ROG) plans for acquisitions. "We're sticking to our previous strategy. This includes targeted, small acquisitions and partnerships like the ones we have carried out in recent months," Chief Executive Officer Severin Schwan told business newspaper Finanz und Wirtschaft. "We take a look at everything. But at present the calculations only add up in the fewest cases," Schwan said, "We have to weigh up internal and external opportunities. It can't be that we have to put important internal opportunities on ice because of too-expensive acquisitions."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO6:GR €27.37 EUR -0.049

RHO6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.59 USD -0.20
Gilead Sciences Inc $91.46 USD +1.62
Johnson & Johnson $102.11 USD 0.00
Novartis AG SFr.79.40 CHF -0.55
Sanofi €76.33 EUR +0.35
View Industry Companies
 

Industry Analysis

RHO6

Industry Average

Valuation RHO6 Industry Range
Price/Earnings 20.9x
Price/Sales 4.5x
Price/Book 12.7x
Price/Cash Flow 17.0x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.